OSE Immunotherapeutics To Present at 'Immuno-Oncology Summit Europe' and at 'Tumor Myeloid-Directed Therapies Summit' In London and Boston streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
A new protection covering CLEC-1 antagonists until 2037Patent also granted in Japan and notice of allowance granted in the USNANTES, France (BUSINESS WIRE) Regulatory News:OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced the grant of a new patent from the European Patent Offic.
Shared positive final Phase 3 results for Tedopi in non-small cell lung cancer (NSCLC) patients in secondary resistance after failure with second-line checkpoint inhibitor treatment. Received